Sphingosine kinase 2 (SK2) targeting in the treatment of multiple myeloma: preclinical and phase I studies of opaganib, an SK 2 inhibitor, in multiple myeloma
Publication
, Conference
Kang, Y; Fan, S; Sundaramoorthy, P; Gasparetto, C; Long, G; Garrett, A; Sellars, E; Mcintyre, J; Maines, L; Ben-Yair, VK; Smith, C; Plasse, T
Published in: EUROPEAN JOURNAL OF CANCER
November 1, 2018
Duke Scholars
Published In
EUROPEAN JOURNAL OF CANCER
EISSN
1879-0852
ISSN
0959-8049
Publication Date
November 1, 2018
Volume
103
Start / End Page
E124 / E124
Location
Dublin, IRELAND
Publisher
ELSEVIER SCI LTD
Conference Name
30th EORTC-NCI-AACR Symposium
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1117 Public Health and Health Services
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Kang, Y., Fan, S., Sundaramoorthy, P., Gasparetto, C., Long, G., Garrett, A., … Plasse, T. (2018). Sphingosine kinase 2 (SK2) targeting in the treatment of multiple myeloma: preclinical and phase I studies of opaganib, an SK 2 inhibitor, in multiple myeloma. In EUROPEAN JOURNAL OF CANCER (Vol. 103, pp. E124–E124). Dublin, IRELAND: ELSEVIER SCI LTD.
Kang, Y., S. Fan, P. Sundaramoorthy, C. Gasparetto, G. Long, A. Garrett, E. Sellars, et al. “Sphingosine kinase 2 (SK2) targeting in the treatment of multiple myeloma: preclinical and phase I studies of opaganib, an SK 2 inhibitor, in multiple myeloma.” In EUROPEAN JOURNAL OF CANCER, 103:E124–E124. ELSEVIER SCI LTD, 2018.
Kang Y, Fan S, Sundaramoorthy P, Gasparetto C, Long G, Garrett A, et al. Sphingosine kinase 2 (SK2) targeting in the treatment of multiple myeloma: preclinical and phase I studies of opaganib, an SK 2 inhibitor, in multiple myeloma. In: EUROPEAN JOURNAL OF CANCER. ELSEVIER SCI LTD; 2018. p. E124–E124.
Kang, Y., et al. “Sphingosine kinase 2 (SK2) targeting in the treatment of multiple myeloma: preclinical and phase I studies of opaganib, an SK 2 inhibitor, in multiple myeloma.” EUROPEAN JOURNAL OF CANCER, vol. 103, ELSEVIER SCI LTD, 2018, pp. E124–E124.
Kang Y, Fan S, Sundaramoorthy P, Gasparetto C, Long G, Garrett A, Sellars E, Mcintyre J, Maines L, Ben-Yair VK, Smith C, Plasse T. Sphingosine kinase 2 (SK2) targeting in the treatment of multiple myeloma: preclinical and phase I studies of opaganib, an SK 2 inhibitor, in multiple myeloma. EUROPEAN JOURNAL OF CANCER. ELSEVIER SCI LTD; 2018. p. E124–E124.
Published In
EUROPEAN JOURNAL OF CANCER
EISSN
1879-0852
ISSN
0959-8049
Publication Date
November 1, 2018
Volume
103
Start / End Page
E124 / E124
Location
Dublin, IRELAND
Publisher
ELSEVIER SCI LTD
Conference Name
30th EORTC-NCI-AACR Symposium
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1117 Public Health and Health Services
- 1112 Oncology and Carcinogenesis